INPLASY PROTOCOL

To cite: Wang. For platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction combined with intravenous chemotherapy versus chemotherapy alone. Inplasy protocol 202170063. doi: 10.37766/inplasy2021.7.0063

Received: 20 July 2021

Published: 20 July 2021

Corresponding author:
Wang Yan

906710772@qq.com

Author Affiliation:
XUZHOU Medical University

Support: **None.**

Review Stage at time of this submission: **Data extraction.**

Conflicts of interest:
None declared.

For platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction combined with intravenous chemotherapy versus chemotherapy alone

Wang, Y[1].

Review question / Objective: **The purpose of this study is to investigate the platinum-sensitive recurrent ovarian cancer, secondary surgical cytoreduction combined with intravenous chemotherapy compared with chemotherapy alone, the research method is domestic and foreign RCT experiment and retrospective study, the research object is recurrent ovarian cancer, the intervention measures are: secondary tumor reduction surgery + intravenous chemotherapy vs chemotherapy alone.**
Condition being studied: **Platinum-sensitive recurrent ovarian cancer. Experimental equipment: through searching the databases such as HowNet, Wanfang, VIP, CBM, PubMed, EMBASE and so on, the qualified articles were searched by 2 people for literature qualification examination and 1 person for receipt collection.**

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 20 July 2021 and was last updated on 20 July 2021 (registration number INPLASY202170063).

INTRODUCTION

Review question / Objective: **The purpose of this study is to investigate the platinum-sensitive recurrent ovarian cancer, secondary surgical cytoreduction combined with intravenous chemotherapy compared with chemotherapy alone, the research method is domestic and foreign RCT experiment and retrospective study, the research object is recurrent ovarian cancer, the intervention measures are: secondary tumor reduction surgery +**

intravenous chemotherapy vs chemotherapy alone.

Condition being studied: Platinum-sensitive recurrent ovarian cancer. Experimental equipment: through searching the databases such as HowNet, Wanfang, VIP, CBM, PubMed, EMBASE and so on, the qualified articles were searched by 2 people for literature qualification examination and 1 person for receipt collection.

METHODS

Participant or population: Patients with platinum-sensitive recurrent ovarian cancer.

Intervention: secondary surgical cytoreduction combined with intravenous chemotherapy.

Comparator: Chemotherapy alone.

Study designs to be included: RCT, retrospective study.

Eligibility criteria: Studies will be selected according to the PICOS criteria (Participant, intervention, comparator, outcomes, and study design) outlined in the referred sections. NCCN guidelines recommend platinum sensitive recurrent ovarian cancer, secondary tumor reduction combined with intravenous chemotherapy is not the first-line treatment.

Information sources: HowNet, Wanfang, VIP, CBM, pubmed, Embase.

Main outcome(s): Efficacy, median survival, survival rate, disease-free survival.

Quality assessment / Risk of bias analysis: Cochrane tools.

Strategy of data synthesis: Stata software was selected for data analysis. If i > 50% and P < 0.1, heterogeneity was considered. There was heterogeneity to select random effect combined with effect quantity, and there was no heterogeneity to select fixed effect combined with effect quantity.

Subgroup analysis: The residual cancer was less than or equal to 2cm and more than 2cm; The drug withdrawal time is less than or equal to 6m, and the drug withdrawal time is more than 6m.

Sensitivity analysis: Stata software carries out sensitivity analysis, and the sensitivity of the article is reversed by deleting the change of the effect after one of them.

Country(ies) involved: China.

Keywords: platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction, chemotherapy.

Contributions of each author:

Author 1 - Wang Yan.
Email: 906710772@qq.com